

**A. M. GHELANI & COMPANY**  
**CHARTERED ACCOUNTANTS**

224, Champaklal Industrial Estate  
Sion-Koliwada Road, Sion (East),  
Mumbai - 400 022.  
Tel : 2402 4909 / 8739  
Fax : 2407 1138  
E-mail : [amghelaniandco@gmail.com](mailto:amghelaniandco@gmail.com)

**AJIT M. GHELANI**  
**B.Com (Hons), F.C.A., GRAD. C.W.A.**

**CHINTAN A. GHELANI**  
**B.Com (Hons), F.C.A., C.S**

To,  
The Board of Directors  
**Kilitch Drugs (India) Limited**

**LIMITED REVIEW REPORT OF THE UNAUDITED STANDALONE RESULTS OF KILITCH DRUGS (INDIA) LIMITED FOR THE QUARTER ENDED 30TH JUNE, 2018**

1. We have reviewed the accompanying statement of unaudited standalone financial results of KILITCH DRUGS (INDIA) LIMITED (the 'Company') for the quarter ended 30th June, 2018 being submitted by the Company pursuant to the requirement of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016.
2. The preparation of the Statement in accordance with the recognition and measurement principles laid down in Indian Accounting Standard 34, Interim Financial Reporting, prescribed under Section 133 of the Companies Act, 2013 read with Rule 3 of Companies (Indian Accounting Standards) Rules, 2015 and SEBI Circular No. CIR/CFD/FAC/62/2016 dated July 5, 2016 is the responsibility of the Company's management and has been approved by the Board of Directors of the company. Our responsibility is to express a conclusion on the Statement based on our review.
3. We conducted our review in accordance with the Standard on Review Engagements (SRE) 2410, "Review of Interim Financial Information Performed by the Independent Auditor of the Entity" issued by the Institute of Chartered Accountants of India. This standard requires that we plan and perform the review to obtain moderate assurance as to whether the Statement is free of material misstatement. A review is limited primarily to inquiries of company personnel and analytical procedures applied to financial data and thus provide less assurance than an audit. We have not performed an audit and accordingly, we do not express an audit opinion.
4. Based on our review conducted as above, nothing has come to our attention that causes us to believe that the accompanying statement prepared in accordance with the recognition and measurement principles laid down in applicable Indian Accounting Standards ('Ind AS') specifies under Section 133 of the Companies Act, 2013, read with relevant rules issued thereunder and other recognised accounting practices and policies has not disclosed the information required to be disclosed in terms of Regulation 33 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015, read with SEBI Circular No. CIR/CFD/FAC/62/2016 dated 5th July, 2016, including the manner in which it is to be disclosed, or that it contains any material misstatement.

**For A. M. Ghelani & Company**

Chartered Accountants

FRN: 103173W


  
**Chintan Ghelani**

Partner

Membership No.: 104391

Place : Mumbai

Dated : 13th August, 2018



**Encl: Unaudited financial results for the quarter ended 30th June, 2018 of Kilitch Drugs (India) Limited.**

## KILITCH DRUGS (INDIA) LIMITED

STATEMENT OF STANDALONE UNAUDITED FINANCIAL RESULTS FOR THE QUARTER ENDED 30TH JUNE, 2018

Regd. Office:- C-301/2, MIDC, TTC Industrial Area, Pawane Village, Thane-400701

Tel No: 022- 61214100, Email id: info@kilitch.com, Website: www.kilitch.com

(Rs. In Lakhs)

Sr. No.	Particulars	STANDALONE			
		Three Months Ended			Year Ended
		30-06-2018	31-03-2018	30-06-2017	31/03/2018
		Unaudited	Audited	Unaudited	Audited
1	<b>Income from operations</b>				
	Net Sales/ Income from operations	2,797.34	1,569.78	675.82	5,045.78
	Other Income	236.77	95.52	20.66	277.91
	<b>Total Income from Operations</b>	<b>3,034.11</b>	<b>1,665.30</b>	<b>696.48</b>	<b>5,323.69</b>
2	<b>Expenses</b>				
	(a) Cost of Materials Consumed	1,765.53	772.45	351.42	2,635.11
	(b) Changes in Inventories of Finished Goods, Work-in-Progress and Stock-in-Trade	(55.31)	97.60	(42.36)	(44.20)
	(c) Employee Benefit Expenses	136.37	112.48	99.86	421.93
	(d) Finance Cost	-	-	-	-
	(e) Depreciation and Amortisation Expenses	26.01	31.11	28.04	119.23
	(f) Export Product Registration/Commission	64.06	120.75	31.34	339.43
	(g) Other Expenses	563.35	225.56	249.49	1,136.55
	<b>Total Expenses</b>	<b>2,500.01</b>	<b>1,359.95</b>	<b>717.79</b>	<b>4,608.05</b>
3	<b>Profit / (Loss) before Exceptional items (1-2)</b>	534.10	305.35	(21.31)	715.64
4	Exceptional Items	-	-	-	-
5	<b>Profit / (Loss) from ordinary activities before tax (3+4)</b>	534.10	305.35	(21.31)	715.64
6	Tax Expenses:				
	Current Tax	59.12	13.48	-	33.48
	Deferred Tax	58.07	63.59	(9.75)	62.57
7	<b>Net Profit / (Loss) after Tax for the period from Continuing Operations (5-6)</b>	416.91	228.28	(11.56)	619.59
8	Other Comprehensive Income (after tax)	(29.59)	(46.16)	62.12	66.81
9	<b>Total Comprehensive Income (after taxes) (7+8)</b>	387.32	182.12	50.56	686.40
10	Paid-Up equity share capital (Face Value Rs 10 per share)	1,373.18	1,373.18	1,323.18	1,373.18
11	Other Equity				11,746.37
12	<b>Earnings per share</b>				
	(a) Basic (not annualised)	3.04	1.72	(0.09)	4.68
	(b) Diluted (not annualised)	2.72	1.60	(0.09)	4.40

**Notes:**

- The above results as reviewed by the Audit Committee have been taken on record by the Board of Directors at their meeting held on 13th August, 2018.
- The statement has been prepared in accordance with companies (Indian Accounting Standards) Rule, 2015 (Ind AS) prescribed under section 133 of the Companies Act, 2013 and other recognised accounting practices and policies to the extent applicable..
- The Company is predominantly engaged in the business of Pharmaceuticals, whose results are reviewed regularly by chief operating decision maker for making decisions about resource allocation and performance assessment. As such, there are no separate reporting segments as per Ind-AS108.
- The figures for the quarter ended 31st March, 2018 are the balancing figures between the audited figures in respect of the full financial year and the year-to-date figures up to the third quarter of the said financial year.
- The IND AS 115 Revenue from Contract with customers, mandatory for reporting periods beginning on or after April 1, 2018, replaces the existing revenue recognition requirements. The application of IND AS 115 has not impacted the company's accounting for recognition of revenue.
- The figures for the corresponding previous periods have been restated/regrouped, wherever necessary, to make them comparable with the current periods.



For and on behalf of the Board

  
**Mukund P. Mehta**  
 Managing Director

